Meibomianitis (Meibomitis): Causes and Treatments
- Inflammation of the meibomian glands
- A subtype of posterior blepharitis
- A form of meibomian gland dysfunction (MGD)
- Most common cause of evaporative dry eye disease.
Definition
The International Workshop on Meibomian Gland Dysfunction defines MGD as a “chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion”. When MGD is accompanied by clinically apparent inflammation — visible lid margin redness, telangiectasia, and turbid or thickened secretions — it is termed meibomitis or meibomianitis.
Causes and Risk Factors
Obstructive Mechanisms
- Hyperkeratinization of the meibomian gland duct epithelium leads to terminal duct obstruction, reduced meibum secretion, cystic dilation, and eventual acinar atrophy.
- Stagnation of meibum within obstructed glands promotes bacterial proliferation and secondary inflammation.
Microbial Factors
- Bacterial colonization — Proliferation of commensal bacteria (e.g., Staphylococcus spp.) within the meibomian glands produces lipolytic enzymes that alter meibum composition and drive inflammation.
- Demodex mite infestation — Demodex brevis inhabits the meibomian glands and can block gland orifices, inducing MGD and secondary meibomitis. Demodex folliculorum infests the eyelash follicles and may cause anterior blepharitis that coexists with posterior disease. Cylindrical dandruff at the lash base is highly suggestive of Demodex infestation.
Systemic and Dermatologic Associations
- Acne rosacea — One of the most important systemic associations; ocular rosacea frequently manifests as posterior blepharitis/meibomitis.
- Seborrheic dermatitis — Oily, greasy scaling of the lid margin with overlap into MGD.
- Fibrosing conjunctival disorders — Trachoma, erythema multiforme, and ocular cicatricial pemphigoid can cause secondary MGD.
Hormonal and Age-Related Factors
- Androgen deficiency reduces meibocyte lipid production via downregulation of androgen receptor (AR) and PPARγ signaling, contributing to altered meibum composition and gland atrophy.
- Prevalence of MGD increases significantly with age, particularly above 50 years.
Other Contributing Factors
- Use of isotretinoin (causes meibomian gland atrophy).
- Contact lens wear, giant papillary conjunctivitis, and environmental factors (low humidity, prolonged screen use).
Treatments
Conservative / First-Line Therapy
- Warm compresses — Soften meibum, relieve duct obstruction, and improve gland function. Recommended as the mainstay of treatment.
- Lid hygiene — Mechanical cleansing of the eyelid margins (eyelid scrubs, baby shampoo, or commercial lid wipes) reduces bacterial load.
- Meibomian gland expression/massage — Manual expression of inspissated meibum from the glands.
- Artificial tears — Lipid-containing lubricants to supplement the deficient tear film lipid layer.
Topical Pharmacological Therapy
- Topical antibiotics — Azithromycin ophthalmic solution has both antibacterial and anti-inflammatory properties.
- Topical corticosteroids — Short courses of low-dose glucocorticoids (e.g., loteprednol etabonate) for acute flares; requires monitoring for steroid-induced glaucoma and cataracts.
- Antibiotic–steroid combinations — Topical combination drops/ointments for moderate-to-severe disease.
- Topical cyclosporine A (Restasis, Cequa) — Immunomodulatory agent approved for dry eye disease; may be used as an adjunct, though evidence for superiority over placebo in MGD specifically is limited].
- Lifitegrast 5% (Xiidra) — LFA-1/ICAM-1 antagonist approved for dry eye; has shown benefit in inflammatory MGD, with improvement in eye dryness, corneal staining, and eyelid redness compared with thermal pulsation in one RCT.
Systemic Pharmacological Therapy
- Oral tetracyclines — Doxycycline (e.g., 50–100 mg daily for 6–12 weeks) or minocycline; exert anti-inflammatory, lipid-modulating, and anti-bacterial effects on the meibomian glands.
- Oral azithromycin — Pulsed regimens (e.g., 500 mg day 1, then 250 mg days 2–5) offer a shorter course with fewer gastrointestinal side effects; one RCT showed comparable or superior efficacy to doxycycline.
- Omega-3 fatty acid supplementation — May improve MGD symptoms and tear film stability.
Demodex-Directed Therapy
- Tea tree oil (terpinen-4-ol) — Effective for MGD associated with Demodex infestation; applied as lid scrubs.
- Lotilaner 0.25% ophthalmic solution (Xdemvy) — FDA-approved for Demodex blepharitis.
In-Office Procedural Treatments
- Thermal pulsation (LipiFlow) — Automated device applying controlled heat (41–43°C) and pulsatile pressure to the eyelids for 12 minutes; may improve meibomian gland function and dry eye symptoms compared with warm compresses, though long-term durability is uncertain.
- Intense pulsed light (IPL) therapy — Broad-spectrum light applied to the periocular skin; when combined with meibomian gland expression, may improve tear film stability, ocular surface staining, and lipid layer thickness.
- Meibomian gland probing — Intraductal probing to relieve obstruction in refractory cases.
- Other thermal devices — TearCare, MiBoFlo, and Systane iLux systems offer alternative in-office heat/expression modalities.
Complications of Untreated Meibomianitis
If left untreated, meibomitis can cause inflammation of the adjacent ocular surface, leading to:
- Meibomian keratoconjunctivitis — corneal cellular infiltrates, neovascularization, and superficial punctate keratopathy.
- Progressive meibomian gland dropout (acinar atrophy), which is considered a permanent pathological change.
- Chronic evaporative dry eye disease.